Literature DB >> 23545824

[Meta analysis of acupuncture in the treatment of optic atrophy].

Yanli Dai1, Ming Liu, Yixin Zhang, Shihui Wei, Houbin Huang.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of acupuncture for optic atrophy.
METHODS: All the randomized controlled trials (RCTs) on optic atrophy treatment with acupuncture were included after retrieving the PubMed, Embase, Cochrane Library, CBM, CNKI, VIP, Wanfang database from their establishment to November 2012. The bibliographies of the included studies were retrieved as well. The quality of RCTs meeting the inclusion criteria was evaluated and the data were extracted. Meta-analyses were performed with Stata 11.2 software.
RESULTS: Thirteen RCTs involving 1180 eyes were included. Meta-analyses showed that the effect of acupuncture or combined with medicine was superior to medicine alone in terms of total effectiveness [OR=3.281, 95% CI ( 2.517, 4.278)], visual acuity [3.287, 95% CI (2.193, 4.925)], and visual field [3.215, 95% CI (1.580, 6.543)]. The visual sensitivity and P-VEP test showed the similar results.
CONCLUSION: Acupuncture is superior to medicine in terms of improved visual acuity, visual field and P-VEP. However, large samples, and high-quality studies are needed for stronger evidence.

Entities:  

Mesh:

Year:  2013        PMID: 23545824     DOI: 10.3969/j.issn.1672-7347.2013.03.012

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  2 in total

Review 1.  Manual Acupuncture for Optic Atrophy: A Systematic Review and Meta-Analysis.

Authors:  Fang-Yuan Zhi; Jie Liu; Xiao-Peng Ma; Jue Hong; Ji Zhang; Dan Zhang; Yue Zhao; Li-Jie Wu; Yan-Ting Yang; Dan-Yan Wu; Chen Xie; Ling-Xiang Wu; Cui-Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-01-01       Impact factor: 2.629

2.  Acupuncture treatment for optic atrophy: A protocol for systematic review.

Authors:  Ping-Ping Zhou; Peng Sun; Hong-Wei Liu; Yan Meng
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.